dr. daver on the tolerability of magrolimab plus azacitidine in aml/mds
Published 4 years ago • 155 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:22
dr. daver on updated findings with magrolimab/azacitidine in mds
-
1:09
dr. daver on the rationale of azacitidine and nivolumab in acute myeloid leukemia
-
1:49
dr. daver on results of a combination study with azacitidine/nivolumab in aml
-
5:36
david sallman: magrolimab plus azacitidine effective in mds and aml
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
6:26
magrolimab with azacitidine in patients with aml
-
5:22
magrolimab azacitidine in mds and aml
-
2:26
enhance-2: phase iii study of magrolimab plus azacitidine in untreated tp53-mutant aml
-
1:31
advances in mds treatment: the promise of magrolimab plus azacitidine
-
2:15
dr. daver on the utility of maintenance therapy in aml
-
1:08
dr. daver on immune checkpoint pathways in aml
-
1:26
dr. sallman on apr-246 plus azacitidine in tp53-mutant mds and aml
-
1:57
dr. cluzeau on the efficacy of apr-246/azacitidine in tp53-mutated mds and aml
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
2:26
magrolimab plus azacitidine in treatment-naïve aml
-
7:37
magrolimab in tp53-mutated aml and mds: what are the latest updates from eha2022?
-
7:05
combining the novel anti-cd47 antibody magrolimab with azacitidine in patients with tp53-mutant aml
-
5:25
naval daver on adding magrolimab to aml backbone treatment
-
5:48
magrolimab in combination with azacitidine in untreated aml